Impax Laboratories, Inc. (NASDAQ:IPXL) has obtained a mean price target of $29.21 by market experts. The research group First Call has reached this mean recommendation by taking into account the recommendations of leading analysts in the market. These market experts have disclosed projected earnings of $0.56 a share for the near-term quarter and $1.59 for this year.
The technical analysis of Impax Laboratories, Inc. clearly shows that the moving average of 50-days of Impax Laboratories, Inc. (NASDAQ:IPXL) stock is $27.07, and is trading $-3.04 points away or -11.22% from its 50-day moving average of $27.07. Further it is trading $-7.17 or -22.99% away its 200-day moving average of $31.20.
The 52-week high of Impax Laboratories, Inc. (NASDAQ:IPXL) was $46.10 while $20.97 is the low in the same period. This state Impax Laboratories, Inc. shares price has to travel more than $-22.07 to register a new high of 52-weeks or drop +14.59% to touch a new 52-week low point. MA here stands for moving average.
Taking the valuation aspect to reach the estimation of Impax Laboratories, Inc., investors use price-to-earnings ratio, which is truncated as P/E ratio. It assesses shares price by the relative expense of the stock. Impax Laboratories, Inc. (NASDAQ:IPXL) ratio came in at 50.91, which was derived by dividing current price of stock by yearly earnings. Impax Laboratories, Inc. stock recorded a close of $24.03 in last trading session, reaching a market cap of $1.71B.
Investors calculate the Price-to-Earnings-Growth ratio to get a clear view on the valuation of a firm. In the case of a higher PEG ratio, the shareholders look to sell their stock holdings. The undervalued stock has a PEG ratio of 0 or 1 while the fairly valued stock has the ratio of 1 and 2. The Impax Laboratories, Inc. (NASDAQ:IPXL) PEG ratio is at 0.67.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...